NEW YORK, Jan. 25, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against PixarBio Corporation (“PixarBio” or the “Company”) (OTC:PXRB) in the United States District Court for the District of New Jersey on behalf of purchasers of PixarBio (1) pursuant and/or traceable to PixarBio’s private placement that closed on October 30, 2016; and/or (2) publicly traded on the open market from October 31, 2016 through January 20, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for PixarBio investors under the federal securities laws.
According to the Complaint, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the market for the Company’s securities exhibited manipulative or deceptive activities; (2) the Company’s assertions in press releases, third-party promotional materials, and PixarBio’s Form S-1 concerning, among other things, PixarBio’s business combinations and current shareholders; the identity and qualifications of key shareholders and employees and PixarBio’s current and prospective development efforts lacked veracity; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 



